Shaily Lakhanpal, MD
Hematology & Oncology · Birmingham, ALNPI 1538192570
Payments from drug & device makers
Across 861 payments — averaging $657.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$297K
- Pfizer$157K
- Puma Biotechnology, Inc.$22K
- AstraZeneca$21K
- G1 Therapeutics, Inc.$16K
- AbbVie$15K
- plus $37K from 54 others
Across 23 payments — averaging $1492.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$31K
- F. Hoffmann-la Roche AG$3K
What the payments were for
- Consulting fees$5,00514%
- Speaking & faculty fees$12,08535%
- Travel & lodging$1,9316%
- Food & beverage$13,78839%
- Education$4341%
- Other$1,7455%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$5,005
- IBRANCE$1,850
- Oral Paclitaxel$1,250
- Encequidar$1,250
- GAVRETO$250
- SIR-Spheres Microspheres$135
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$118
How this compares
$565,745 in reported general payments places this provider in the 85th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 75 | $1,133,786 |
| CalquenceAcalabrutinib Maleate | 58 | $796,349 |
| CabometyxCabozantinib S-Malate | 27 | $669,789 |
| BrukinsaZanubrutinib | 46 | $648,489 |
| Lenalidomide | 60 | $625,496 |
| JakafiRuxolitinib Phosphate | 22 | $383,470 |
| KisqaliRibociclib Succinate | 23 | $372,795 |
| PomalystPomalidomide | 23 | $341,996 |
| LytgobiFutibatinib | 13 | $333,183 |
| DopteletAvatrombopag Maleate | 11 | $284,071 |
| IbrancePalbociclib | 16 | $229,348 |
| XtandiEnzalutamide | 11 | $155,795 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 24 | $120,472 |
| OrgovyxRelugolix | 37 | $99,927 |
| EliquisApixaban | 124 | $77,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $802 | $1,133,78675 claims |
| AstraZenecaCalquence | $20,695 | $796,34958 claims |
| Exelixis Inc.Cabometyx | $131 | $669,78927 claims |
| PfizerIbrance, Octagam, Eliquis | $157,060 | $426,881164 claims |
| Incyte CorporationJakafi | $275 | $383,47022 claims |
| NovartisKisqali | $3,101 | $372,79523 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $14,630 | $341,99623 claims |
| Astellas Pharma US IncXtandi | $100 | $155,79511 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $31 | $99,92737 claims |
| Johnson & JohnsonXarelto | $472 | $18,89320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Luciano CostaBirmingham$32.8M
- Amitkumar MehtaBirmingham$18.6M
- Erica Stringer-ReasorBirmingham$18.1M
- Susan BalBirmingham$11.3M
- Pankit VachhaniBirmingham$7.9M
- Mehmet AkceBirmingham$5.4M
- Mayur NarkhedeBirmingham$4.9M
- Christos VaklavasBirmingham$4.9M
- Lisle NabellBirmingham$3.3M
- Omer JamyBirmingham$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.